目的：探讨阿立哌唑与利培酮治疗脑血管疾病所致精神障碍的临床疗效及安全性。方法将20例脑血管疾病所致精神障碍患者随机分为两组，分别予以阿立哌唑和利培酮治疗，观察6周。于治疗前后采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组阳性与阴性症状量表评分较治疗前显著降低（P＜0．01），同期两组间比较差异无显著性（P＞0．05）；阿立哌唑组不良发应发生率低于利培酮组，但差异无显著性（P＞0．05）。结论阿立哌唑治疗脑血管疾病所致精神障碍疗效显著，与利培酮相当，但安全性更高。%Objective To explore the efficacy and safely of aripiprazole and ris‐peridone in the treatment of mental disorders due to cerebrovascular disease (MD‐CD) . Methods Twenty 20 MDCD patients were randomly assigned to two groups and treated with aripiprazole or risperidone for 6 weeks .Efficacies were assessed with the Positive and Negative Syndrome Scale (PANSS) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the PANSS scores of both groups lowered more significantly compared with pretreatment (P<0 .01) .Contemporane‐ous group comparisons showed no significant differences (P>0 .05);the incidence of adverse reactions was lower in aripiprazole than risperidone group ,but difference wasn’t significant (P>0 .05) .Conclusion Aripiprazole equivalent to risperidone has an evident effect in the treatment of MDCD ,but aripiprazole’s safety is higher .
展开▼
